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Immune checkpoint inhibitors have revolutionized cancer therapy leading to excep-
tional success. However, there is still the need to improve their efficacy in non-
responder patients. Natural killer (NK) cells represent the first line of defence against
tumours, due to their ability to release immunomodulatory cytokines and kill target
cells that have undergone malignant transformation. Harnessing NK cell response will
open new possibilities to improve control of tumour growth. In this respect inhibitory
checkpoints expressed on these innate lymphocytes represents a promising target
for next-generation immunotherapy. In this review, we will summarize recent evi-
dences on the expression of NK cells receptors in cancer, with a focus on the inhibi-
tory checkpoint programmed cell death protein 1 (PD-1). We will also highlight the
strength and limitations of the blockade of PD-1 inhibitory pathway and suggest new
combination strategies that may help to unleash more efficiently NK cell anti-tumour
response.
Abbreviations: AbE, abscopal effect; AML, acute myeloid leukaemia; BM, bone marrow; CAR, chimeric antigen receptor; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; DCs, dendritic
cells; Gal-9, galectin-9; GvDH, graft versus host disease; HMGB-1, high-mobility group box 1; ICIs, immune checkpoint inhibitors; ITAM, immunoreceptor tyrosine-based activation motif; ITIM,
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1 | INTRODUCTION
Natural Killer (NK) cells are potent effector cells that play a pivotal
role in the innate response against infections by viruses and, more
importantly, against tumours growth, preventing tumour spreading
and metastases. Upon activation, NK cells elicit a strong cytolytic
activity and release chemokines and cytokines able to orchestrate
early inflammatory responses. Thus, NK cells have an essential role in
the first-line defence of the innate immune responses and modulate
the subsequent activation of the adaptive immune system (Moretta,
Bottino, Mingari, Biassoni, & Moretta, 2002; Moretta et al., 2004;
Sivori, Vacca, et al., 2019). Originally, NK cells were thought to reside
primarily in peripheral blood, bone marrow and spleen but recent evi-
dences could demonstrate their presence in lymph nodes and other
non-lymphoid organs such as the uterus, liver and lung (Shi, Ljunggren,
La Cava, & Van Kaer, 2011).
The mechanisms of action of NK cells remained a mystery for
many years until the ‘missing self’ hypothesis, proposed in the late
1980s, revealed that NK cells, by sensing the absence of major his-
tocompatibility complex class I (MHC-I) on target cells, are able to
discriminate between healthy and virus-infected or tumour cells
(Ljunggren & Karre, 1990). This hypothesis was confirmed by the
discovery, in mice and human NK cells, of MHC-specific receptors
able to deliver inhibitory signals that block NK cell cytotoxicity
(Moretta et al., 1990; Ciccone et al., 1992; Moretta et al., 1993;
Moretta, Bottino, et al., 1996). Recognition of self-MHC-I mole-
cules represents the most important mechanism to protect self-
cells from NK cell killing. The discovery that ‘off’ signals are
required to prevent NK-mediated autoreactivity suggested that ‘on’
signals should be present as well and be responsible for NK cell
activation. Indeed, several surface receptors able to promote NK
cell cytotoxicity were subsequently identified and characterized
(Moretta et al., 2001; Moretta et al., 2004). Triggering of NK acti-
vating receptors occurs through binding with specific (non-MHC)
ligands de novo expressed or overexpressed in stressed cells and,
more importantly, in virus-infected or tumour-transformed cells.
However, both tumour cells and tumour micro-environment can
dampen NK cell-mediated anti-tumour activity by modulating the
membrane expression of activating receptors (see below). The fol-
lowing paragraphs will analyse the NK cell receptors with particular
regard to the inhibitory checkpoints and their important role as
attractive therapeutic targets to enhance anti-tumour immune
responses. In addition, we will discuss recent data indicating that
different combined immunotherapies may represent new therapeu-
tic approaches.
2 | NATURAL KILLER CELL RECEPTORS
2.1 | Inhibitory and activating receptors
NK cell function is regulated by an array of inhibitory and activating
receptors. As mentioned before, the inhibitory receptors specific for
human leukocyte antigen class I (HLA-I) molecules provide the most
important regulation of NK cells activity. Two main different types
of HLA-I-specific inhibitory receptors have been identified in NK
cells and are represented by the CD94/killer cell lectin-like
receptor C1 (NKG2A) heterodimer and the members of the killer
immunoglobulin (Ig)-like receptor (KIR) family (Moretta et al., 2014).
Killer cell lectin like receptor C1 (NKG2A), as designated by Inter-
national Union of Pharmacology (IUPHAR) guide to IMMUNO-
PHARMACOLOGY (Armstrong et al., 2020), is a type II
transmembrane protein containing a lectin-type domain in the
extracellular portion, which specifically recognizes HLA-E, a non-
classical HLA-I molecule with a limited polymorphism (Lopez-Botet
et al., 1997). KIRs are type I transmembrane receptors that specifi-
cally recognize shared polymorphic determinants of HLA-A, HLA-B
and HLA-C molecules (Moretta et al., 1993). Importantly, KIR and
NKG2A may be expressed also by T lymphocytes upon prolonged
activation (Mingari et al., 1995; Mingari et al., 1996; Mingari, Mor-
etta, & Moretta, 1998; Mingari, Ponte, et al., 1998) or exposure to
TGFβ (Bertone et al., 1999). Their expression may limit Tcell func-
tion, a critical event in tumour-infiltrating T lymphocytes.
LIR-1 (LILRB1), another type I transmembrane molecule, belong-
ing to the Ig-like receptor superfamily is another HLA-specific recep-
tor interacting with both classical (HLA-A, HLA-B and HLA-C) and
non-classical (HLA-G) HLA-I ligands (Cosman et al., 1997; Ponte
et al., 1999; Vitale et al., 1999). Despite molecular differences, these
inhibitory receptors, upon interaction with HLA-I ligands, activate
common downstream pathways that transduce inhibitory signals
determining a strong inhibition of the polarization and release of lytic
granules (Das & Long, 2010). Indeed, they share the cytoplasmic
domain called immunoreceptor tyrosine-based inhibitory motif (ITIM)
that is phosphorylated upon ligand interaction and recruits the tyro-
sine phosphatase SH2 domain-containing phosphatase (SHP)-1 and
(SHP)-2 (Lanier, Corliss, Wu, Leong, & Phillips, 1998; Moretta, Bottino,
et al., 1996). In turn, these phosphatases activate a downstream cas-
cade to turn off NK cell function. It must be noted that at least one
receptor specific for classical HLA-I molecules is expressed by NK
cells allowing the whole NK cell pool to detect the loss of even a sin-
gle allele on self-cell, an event frequently occurring in transformed
tumour cells (Garrido, 2019).
The activity of inhibitory receptors is required to counterbal-
ance the function of activating receptors. The major activating NK
receptors are represented by the Natural Cytotoxicity Receptors
(NCRs) that consist of three molecules named NKp46 (Pessino
et al., 1998; Sivori et al., 1997), NKp44 (Vitale et al., 1998) and
NKp30 (Pende et al., 1999). NCRs are type I transmembrane
receptors, belonging to the immunoglobulin-like family and their
transmembrane domains contain a positively charged amino acid
required for the interaction with the Immunoreceptor tyrosine-
based activation motif (ITAM) sequence present in adaptor poly-
peptides (Barrow, Martin, & Colonna, 2019). NCRs, selectively
expressed by NK cells (with the exception of NCR+ ILC3), repre-
sent the most reliable markers to identify these cells and play a
pivotal role in NK-mediated tumour cells killing. In addition, it has
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been demonstrated that the magnitude of the cytolytic activity
towards NK-susceptible target cells correlates with NCRs surface
density on NK cells (Sivori et al., 2000). Different ligands, such as
virus-derived molecules and/or intracellular proteins (i.e. the nuclear
protein PCNA) that are expressed in response to stress or during
tumour transformation, have been shown to interact with NCRs
extracellular regions. In addition, it has been recently demonstrated
that also the extracellular ligand Nidogen-1 and the soluble plasma
glycoprotein called complement factor P/properdin can interact
with NKp44 and NKp46, respectively (Gaggero et al., 2018; Narni-
Mancinelli et al., 2017; Sivori, Vacca, et al., 2019).
NKG2D (HER2), a type II transmembrane and C-type lectin-like
molecule, represents another important NK cell-activating receptor.
Also, its ligands, namely, ULBPs and MICA/B, are overexpressed in
infected and tumour cells (Lanier, 2015). Other triggering surface
molecules are represented by co-receptors that include 2B4 and
NTB-A, as well as DNAM-1, NKp80 and CD59 whose function is
to amplify NK cell triggering (Moretta et al., 2014). However, to
exert their activity, they rely on the simultaneous engagement of
one or another triggering receptor (such as NCRs and/or NKG2D).
Thus, it can be concluded that the balance of signals derived
from activating and inhibitory receptors determines if NK cells will
exert their cytotoxic activity or remain inactive. As mentioned
before, the inhibitory receptors specific for HLA-I, KIRs and
NKG2A, control NK cells autoreactivity. Under normal conditions,
the interaction between inhibitory receptors and their ligands inac-
tivates NK cells, preventing killing of healthy cells, with the remark-
able exception of the NK-mediated editing of Dendritic cells (DCs),
which failed to undergo proper maturation (Moretta et al., 2002).
During virus infection or tumour progression, transformed cells
down-regulate or even lose HLA-I expression, becoming susceptible
to NK-mediated cell lysis. For example, this is particularly important
during the initial phase of viral infection, when T lymphocytes have
not expanded sufficiently to mediate protection and NK cells play
a primary role in limiting virus spreading. It is well known that also
tumour cells may express low levels of HLA-I molecules. However,
loss of HLA-I expression is not sufficient to induce NK-mediated
cell killing, which will occur only if triggering receptors have also
been properly engaged by specific ligands present on the surface
of target cells (Moretta et al., 2004). Indeed, such ligands for acti-
vating receptors are usually absent or expressed at low levels in
resting healthy cells, while they are up-regulated or even expressed
de novo at the surface of stressed normal cells or virus-infected or
transformed tumour cells. In this context, while stressed healthy
cells express normal or increased levels of HLA-I molecules, which
efficiently engage the inhibitory receptors, in virus-infected or
tumour cells, the activating signal will overcome the signalling
mediated by the inhibitory receptors promoting target cell killing
and cytokine release.
Notably, KIRs and the other HLA-I-specific inhibitory receptors
should be considered as the first discovered inhibitory checkpoints
controlling NK cells and, in some instances, T-cell function (relevant to
anti-tumour defence).
2.2 | Inhibitory checkpoint receptors
In addition to the inhibitory receptors specific for HLA-I molecules,
additional inhibitory checkpoints (including PD-1, TIM-3, LAG-3, etc.),
primarily involved in the maintenance of immune cell homeostasis,
have been described in NK cells. Most of these inhibitory checkpoints
are not expressed by resting NK cells. However, under pathological
conditions, their expression can be de novo induced upon interaction
with specific ligands frequently expressed on the surface of tumour
cells. In this context, checkpoint receptors can affect NK cell function
facilitating tumour immune escape. A major inhibitory checkpoint is
represented by programmed cell death protein 1 (PD-1) that was
originally discovered to be expressed on T cells and to induce
programmed cell death during T-cell thymic selection (Ishida, Agata,
Shibahara, & Honjo, 1992). Even though PD-1 was initially described
on T, B and myeloid cells, it has been recently described also on NK
cells (see below) (Pesce et al., 2017) (Huang, Francois, McGray,
Miliotto, & Odunsi, 2017). PD-1 is a type I transmembrane glycopro-
tein composed of an IgV-type extracellular domain, which belongs to
the CD28/cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
subfamily of the Ig superfamily (Chamoto, Al-Habsi, & Honjo, 2017).
Structural and biochemical analyses demonstrated that, due to the
lack of membrane-proximal cysteine residues required for
homodimerization, PD-1 is monomeric in solution as well as on cell
surface (Zhang et al., 2004). Its cytoplasmic domain contains two tyro-
sine residues, the membrane-proximal one constitutes the ITIM
region, while the other domain is represented by the immunoreceptor
tyrosine-based switch motif (ITSM) (Okazaki & Honjo, 2007)
(Figure 1). Despite ITIM is often associated with inhibitory receptors
(including KIRs and NKG2A) being required for the activation of the
inhibitory cascade, the tyrosine residue in the ITSM has been shown
to be essential for PD-1 inhibitory function (Okazaki, Maeda,
Nishimura, Kurosaki, & Honjo, 2001). Indeed, upon antigen stimula-
tion, this tyrosine residue is phosphorylated and recruits SHP-2, which
through dephosphorylation of downstream effector targets, initiates
the inhibitory cascade. The PD-1 ligands are represented by the type I
transmembrane glycoprotein programmed cell death 1 ligand 1 (PD-
L1) and programmed cell death 1 ligand 2 (PD-L2). Expression of PD-
L1 is detectable on haematopoietic cells such as T and B cells, macro-
phages and bone marrow-derived mast cells. In addition, PD-L1 may
be expressed also in non-haematopoietic cells like mesenchymal stem
cells, lung, keratinocytes and vascular endothelium cells (Keir, Butte,
Freeman, & Sharpe, 2008). On the contrary, PD-L2 shows a more
restricted expression which is limited to macrophages, bone marrow-
derived mast cells, dendritic cells and peritoneal B1 cells (Zhong, Tum-
ang, Gao, Bai, & Rothstein, 2007). Importantly, the expression of PD-
L1 and PD-L2 in both lymphoid and non-lymphoid tissues suggests
that this pathway could regulate immune responses not only in target
organs but also in secondary lymphoid organs. In normal condition,
the engagement of the PD-1 pathway regulates immune cell activa-
tion and ensures peripheral tolerance. However, PD-1 ligands (PD-L1
and PD-L2) have been shown to be often expressed also by cells of
different tumours. In this context, the interaction of PD-1 with its
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ligands inhibits NK cell-mediated killing, thus favouring tumour
immune escape. Considering that the PD-1/PD-Ls axis is widely
adopted by different tumour cells to escape the immune system, it is
not surprising that this pathway has been extensively studied to
develop new therapeutic approaches aimed to restore the anti-
tumour immune response (see below). Of notice is also the discovery
of a soluble form of PD-1 (sPD-1); recently different studies have
been focused on sPD-1 possible role as an anti-tumour agent (Elhag
et al., 2012; Nielsen, Ohm-Laursen, Barington, Husby, &
Lillevang, 2005). In this context, clinical studies have investigated the
presence of sPD-1 and its correlation with the overall survival of
patients with different cancers (Kruger et al., 2017; Sorensen,
Demuth, Weber, Sorensen, & Meldgaard, 2016).
In humans, in addition to PD-1, other inhibitory checkpoints
may be expressed on the surface of NK cells. Lymphocyte activa-
tion gene-3 (LAG-3) is a type 1 transmembrane protein with signif-
icant homology to CD4. Compared with PD-1, LAG-3 has a larger
extracellular domain that consists of four Ig-like domains and it is
also characterized by an unusual cytoplasmic tail which contains
domains not found in other inhibitory checkpoints (De Sousa,
Leitner, Grabmeier-Pfistershammer, & Steinberger, 2018) (Figure 1).
LAG-3 binds MHC class II molecules promoting an exhausted pro-
file observed in tumour-infiltrating lymphocytes (TILs). While its
role in the modulation of T-cell proliferation, activation and homeo-
stasis has been extensively studied, LAG-3 effects on NK cell func-
tion are still to be clarified (Kim & Kim, 2018). As for PD-1, a
soluble form of LAG-3, acting as an immune adjuvant has been
identified and clinical-grade sLAG3 has been analysed in phase I
and II clinical trials to favour stimulation of the immune system
(Chiossone & Vivier, 2017).
Tcell immunoglobulin and mucin domain-containing protein
3 (TIM3), a member of the TIM family, is a type I transmembrane pro-
tein containing an N-terminal IgV-like domain and a mucin domain
(Figure 1). Similarly, to LAG-3, TIM3 does not contain classical inhibi-
tory motifs, like ITIM, however phosphorylation of two tyrosine resi-
dues present in its cytoplasmic tail mediates the intracellular signalling
pathway (De Sousa et al., 2018). Several ligands have been found to
associate with TIM3 such as the high-mobility group box 1 (HMGB-1),
galectin-9 (Gal-9), phospatidylserine (PtdSer) and CEACAM-1
(Figure 1). TIM3 expression has been detected in different lymphoid
cells and it has been suggested to be a marker for mature and/or acti-
vated NK cells. An increase of TIM3 expression in NK cells has been
observed in patients with advanced melanoma and has been corre-
lated with the NK cell exhaustion phenotype (Gallois, Silva, Osman, &
Bhardwaj, 2014). Of note, TIM3 is often co-expressed with PD-1 dur-
ing cancer progression and chronic infection.
Other widely studied inhibitory checkpoints are represented by
the T-cell immunoglobulin and ITIM domain (TIGIT) and CD96
(Figure 1). TIGIT and CD96 belong to the Ig superfamily, that includes
also the activating co-receptor DNAM-1. Both receptors contain an
ITIM sequence in their cytoplasmic domains that initiates the inhibi-
tory cascade leading to inhibition of NK cell function, including gran-
ule polarization, cytotoxicity and cytokine secretion (Stanietsky
et al., 2009). TIGIT and CD96 corresponding ligands are represented
by the cell surface nectin and nectin-like CD115 (PVR) and CD112
(PVRL2, nectin-2) molecules that are up-regulated in different
F IGURE 1 Schematic representation of inhibitory checkpoints and their ligands. NK cells express multiple inhibitory checkpoint receptors
such as PD-1, TIM3, LAG-3, TIGIT, CD96, ILT2 and KIR2DL4 that interact with specific ligands expressed on virus-infected or tumour-
transformed cells. The different extracellular and intracellular domains reported illustrate the molecular heterogeneity of these inhibitory
checkpoints. The classical ITIM domain is shared between PD-1, TIGIT, CD96, ILT2 and KIR2DL4, while the ITSM- and ITT-like regions are
present only in PD-1 and TIGIT, respectively. LAG-3 has an unusual cytoplasmic region containing a potential serine phosphorylation motif
(S454), a glutamic acid–proline (EP) repeat and the conserved KIEELE motif that is indispensable for its inhibitory function. TIM3 presents a mucin
domain in the extracellular region while lacks any conserved motifs in the intracytoplasmic tail. KIR2DL4 presents an arginine residue, in the
transmembrane domain, able to interact with FcεRI
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tumours. Considering that CD115 and CD112 are also DNAM-
1-ligands, it is evident that both these inhibitory checkpoints and the
activating co-receptor may compete for the same ligands. Therefore,
TIGIT engagement with CD115 inhibits NK cell function by counter-
balancing the DNAM-1-mediated activating signals. TIGIT can be
detected in resting NK cells and its expression is up-regulated upon
NK cell activation and in tumour-associated NK cells of patients with
colon cancer (Zhang et al., 2018). Indeed, high expression of TIGIT on
tumour-infiltrating NK cells, has been shown to correlate with
reduced cytotoxicity and cytokine release.
The immunoglobulin-like transcript 2, ILT2 (LILRB1) and
KIR2DL4 represent two other important NK cell inhibitory recep-
tors (Lin & Yan, 2018). While ILT2 ( (LILRB1) is expressed on NK
cells, T cells, monocytes, B cells, dendritic cells and myeloid-derived
suppressor cells (MDSCs), KIR2DL4 is predominantly found on
decidual NK cells and cannot be detected on the surface of periph-
eral blood resting NK cells (Koopman et al., 2003; Rajagopalan &
Long, 2012). Regulation of NK cell function by KIR2DL4 is quite
complicated because it is characterized by one ITIM domain in its
intracellular region and, by an arginine residue, in its transmem-
brane domain able to interact with FcεRI. Thus it presents features
of both inhibitory and stimulatory receptors (Rajagopalan &
Long, 2012). ILT2 (LILRB1) belongs to the leukocyte Ig-like recep-
tor subfamily B (LILRB), a group of type I transmembrane glycopro-
tein, and its extracellular region consists of four immunoglobulin
domains, while the cytoplasmic tail is characterized by four ITIM
sequences (Kang et al., 2016). Both ILT2 and KIR2DL4 interact
with the HLA-G molecule. HLA-G in normal condition is expressed
at the fetal–maternal interface and few healthy adult tissues like
cornea, pancreatic isles and thymic medulla (Carosella, Rouas-Freiss,
Tronik-Le Roux, Moreau, & LeMaoult, 2015; Lin & Yan, 2018).
However, its expression can be switched on in pathological condi-
tions, such as cancer, viral infection autoimmune and inflammatory
diseases (Lin & Yan, 2018). Indeed, aberrant HLA-G expression has
been detected in several tumours like ovarian carcinoma, gastric
cancer, breast and lung cancer, and colorectal cancer (Carosella
et al., 2015), and it has been correlated with metastatic status,
advanced tumour stage and poor disease outcome. Indeed, over-
expression of HLA-G is a well-known mechanism used by tumour
cells to avoid and inhibit both the innate and adaptive immune
responses (Li et al., 2017). Thus, HLA-G/ILT2 interaction impairs
NK cells chemotaxis, cytotoxicity, IFN-γ production and
MICA/NKG2D-induced activation (Menier, Riteau, Carosella, &
Rouas-Freiss, 2002; Morandi et al., 2011). For this reason, the
HLA-G/ILT signalling pathway is considered as a new immune
checkpoint and a promising immunotherapy target.
3 | INHIBITORY CHECKPOINTS AS
TARGETS OF IMMUNOTHERAPY
Immunotherapy through immune checkpoint inhibitors (ICIs) results
in increased activation of the immune response and has recently led
to the approval of several new drugs. The first developed approach
was aimed at blocking two key inhibitory receptors that critically
affect peripheral T-cell tolerance and T-cell function: CTLA-4 and
PD-1. CTLA-4 is a CD28 homologue but with much higher affinity
for B7. Thus, the inhibitory signal is mostly due to the ‘subtraction’
of B7 to the costimulatory signal physiologically provided by CD28:
B7 binding and required for T-cell receptor (TCR)-mediated T-cell
activation (Walunas et al., 1994). Anti-CTLA4 blockade with
ipilimumab was the first treatment to prolong the overall survival in
patients with advanced melanoma in randomized trials (Hodi
et al., 2010; Robert et al., 2011). More recently, strategies aimed at
blocking PD-1 have been developed. PD-1 blockade has been shown
to improve the survival and the progression-free survival in patients
with metastatic melanoma and in patients with metastatic squamous
and non-squamous non-small-cell lung cancer (NSCLC) who have
been previously treated with standard therapies. Recently, immuno-
therapy with monoclonal antibodies (mAbs) that target the PD-1/PD-
L1 axis has successfully improved cancer treatment and has been
approved in a variety of cancers, including several solid tumours
(Baitsch et al., 2011; Hamid et al., 2013; Rizvi et al., 2015; Topalian
et al., 2012). Both CTLA-4 and PD-1 have similar negative effects on
T-cell activation, however, while CTLA-4 is rapidly expressed on the
surface of T cells following activation, thus compromising early T-cell
response, PD-1 is expressed on T cells upon exhaustion and acts later
on long-term tolerance maintenance. Although both CTLA-4-
and PD-1-deficient mice develop autoimmune phenotypes
(Nishimura, Nose, Hiai, Minato, & Honjo, 1999; Walunas, Bakker, &
Bluestone, 1996), the severity and timing is different, suggesting that
the two receptors differentially shape the T-cell repertoire and the
immune response. While PD-1-deficient mice take several months to
develop autoimmunity, which it is targeted to specific organs, CTLA-
4-deficient mice develop multi-organ disease and die within 3 weeks,
consistent with the critical physiological role of this receptor for T-
cell homeostatic expansion. Another important difference between
the two checkpoints is that CTLA-4 is expressed by T cells only,
while PD-1 is expressed by other immune cells, also including NK
cells (Fife & Bluestone, 2008). Thus, PD-1 checkpoint blockade
allows broadening the efficacy of immunotherapy by acting on multi-
ple effector lymphocytes and, in particular, on the NK cell compart-
ment, which has recently become the focus of interest for
therapeutic interventions (Andre et al., 2018; Cerwenka &
Lanier, 2018; Mariotti, Quatrini, Munari, Vacca, & Moretta, 2019;
Mingari, Pietra, & Moretta, 2019; Pesce et al., 2019). In this context,
a common strategy to elude T-cell-mediated immune responses is the
down-regulation or loss of expression of HLA-I molecules, which as
has been documented for a large range of epithelial cell cancers and
melanomas (Garrido, 2019; So et al., 2005; Zitvogel, Tesniere, &
Kroemer, 2006). Therefore, while initially immunotherapy was mainly
focused on enhancing Tcell responses, targeting immune checkpoints
expressed on NK cells is now extremely important for advanced
tumours that become ‘invisible’ to T cells. Among the NK cell check-
points, PD-1 expression has been documented in many tumour set-
tings and will be the focus of the next paragraphs.
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4 | PD-1/PD-L AXIS BLOCKADE: AN
EXAMPLE OF IMMUNOTHERAPY TARGETING
AN NK CELL INHIBITORY CHECKPOINT
4.1 | PD-1/PD-L axis in tumours
The PD-1/PD-L1 axis plays a fundamental role in the inhibition of
anti-tumour effector function of CD8+ T cells. Different from T cells,
which express high levels of PD-1 at exhaustion, PD-1 is absent or
expressed at very low levels on peripheral blood NK cells of healthy
donors, with the exception of a minor fraction of cytomegalovirus
(CMV)-seropositive individuals (Pesce et al., 2017). In mice, it was
shown that endogenous glucocorticoids released upon infection with
murine CMV (MCMV) induce PD-1 expression on spleen NK cells
(Quatrini et al., 2018). Regarding human NK cells, recent data would
suggest that persistent stimulation by tumour cells expressing ligands
for activating NK receptors or soluble factors present in the TME may
induce PD-1 surface expression (Pesce et al., 2019) with consequent
impairment of anti-tumour NK effector function. Notably, human NK
cells have been shown to display an intracytoplasmatic pool of PD-1
mRNA and PD-1 protein localized in the Golgi (Mariotti et al., 2019);
however, the stimuli required for its expression on the membrane are
still undefined.
There is clear evidence that tumour cells express the natural
ligands of PD-1 (PD-Ls), as a mean to evade immune attack (Munari,
Zamboni, Lunardi, Marconi, et al., 2018). Recently, different indepen-
dent studies provided evidence for the expression of PD-1 on human
tumour-infiltrating NK cells including multiple myeloma (Benson
et al., 2010), Kaposi sarcoma (Beldi-Ferchiou et al., 2016), ovarian car-
cinoma (Pesce et al., 2017) and digestive and lung cancers (Liu
et al., 2017; Tumino et al., 2019). Of note, in malignant pleural effu-
sions derived from patients with primary or metastatic lung tumours,
PD-1 expression is not only confined to NK cells but is also expressed
by tumour-infiltrating ILC3s (Tumino et al., 2019). It has been shown
that NK cells isolated from pleural effusions could release cytokines
and efficiently kill tumour cells (Croxatto et al., 2017; Vacca, Martini,
Mingari, & Moretta, 2013). However, when these PD-1+ NK cells
interacted with tumour cells expressing PD-Ls, their cytokine produc-
tion was sharply inhibited (Tumino et al., 2019).
4.2 | Strengths and limitations of monoclonal
antibodies targeting the PD-1/PD-L axis in cancer
Monoclonal antibodies acting through PD-1 blockade represent a
major breakthrough in oncology, showing significant clinical success
in the treatment of several types of cancer. There are currently
five approved therapeutic agents on the market targeting the PD-
1/PD-L1 pathway: Nivolumab and pembrolizumab are humanized
IgG monoclonal antibodies directed at the PD-1 receptor, whereas
atezolizumab, durvalumab and avelumab are humanized IgG mono-
clonal antibodies directed at the PD-L1 ligand. Several large-scale
clinical trials showed significant response rates and improvements
in overall survival in a variety of patients with solid tumours
including NSCLC, gastrointestinal carcinomas, squamous cell carci-
nomas of the head and neck (SCCHN), renal cell carcinomas,
urothelial carcinomas, cervical carcinomas and breast carcinomas, as
well as in patients with lymphoma or melanoma. For this reason,
all of these five antibodies have been approved for use as the
first- or second-line treatment (Garon et al., 2015; Reck
et al., 2016) (Borghaei et al., 2015; Rizvi et al., 2015). Each of
these drugs binds to a different epitope on their respective target
and their mechanisms of action consist in blocking the PD-1/PD-
L1 receptor–ligand interaction. A novel class of anti-PD-1 anti-
bodies was recently identified with a different mechanism of action
but with an antagonistic activity comparable with that of
pembrolizumab and nivolumab. These antibodies bind to the oppo-
site face of the PD-1 protein relative to the PD-1–PD-L1 interac-
tion site and act predominantly through the restoration of the
positive signalling transduced by the simultaneous engagement of
CD28 co-receptor (Fenwick et al., 2019). Although the synergistic
effect of these non-blocking anti-PD-1 antibodies with blocking
PD-1 antibodies has only been demonstrated in vitro and in a
mouse tumour model in vivo, their distinct mechanism of action
suggests that they may complement classical immunotherapy by
enhancing the recovery of anti-tumour activity of cytotoxic
lymphocytes.
Despite the successes of the above-mentioned Food and Drug
Administration (FDA)-approved antibodies, only 30–40% of patients
show a response to anti-PD-1 immunotherapy. Response rates vary
widely between cancer types and there is a particular need for predic-
tive biomarkers that can be used to identify patients more likely to
respond to immune checkpoint modulators. To this end, different
tumour features are evaluated prior to the design of the therapy.
These include assays to analyse the level of PD-L1 expression in
tumour cells and DNA sequencing to estimate tumour mutational bur-
den (TMB) (Havel, Chowell, & Chan, 2019). One important critical limi-
tation that may influence the response to the PD-1/PD-L1 axis
blockade is the screening of tumours based on the expression of PD-
L1, which is routinely evaluated by immunohistochemical staining
using different methods (tumour proportion score, combined positive
score and tumour-infiltrating immune cells). This diagnostic test may
guide the decision of the appropriate therapeutic strategy to be
adopted and helps to predict benefits in subgroups of patients,
depending on the degree of biomarker expression at different cut-off
(Sholl et al., 2016) (Figure 2). Higher PD-L1 expression on tumour cells
generally correlates with higher rates of clinical response to treatment
with PD-1/PD-L1 inhibitors. However, this is not always the case, as
clinical responses are also observed in patients with tumours negative
for PD-L1. It is reasonable to think that such discrepancy may be at
least in part explained by the fact that a number of tumours could be
misclassified, in terms of PD-L1 expression, due to different factors
including expression heterogeneity in the tumours, interclone differ-
ences and interobserver/intraobserver variability, as demonstrated in
several reports (Munari et al., 2017; Munari, Rossi, Zamboni, Lunardi,
et al., 2018; Munari, Zamboni, Lunardi, Marchionni, et al., 2018).
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High tumour mutational load has been correlated to better
response to immune checkpoint blockade, because it may generate
novel antigens that are not subject to immune tolerance, thus
improving T-cell-mediated adaptive immune responses (Yarchoan,
Hopkins, & Jaffee, 2017). Therefore, TMB has emerged
as a promising novel biomarker to further aid in patient selection
(Figure 2). High mutation burden is typically observed in
carcinogen-driven tumours such as lung cancer and melanoma and
in tumours caused by germline mutations in genes encoding for
proteins involved in DNA repair and replication. The main limita-
tion of TMB analysis is represented by the high costs of the whole
genome sequencing; therefore, it is limited to malignancies that are
more likely to be highly mutated, and it is often analysed indirectly
through less expensive techniques. Indirect TMB assessment
includes analysis of microsatellite instability status, chromosomal
structural analysis and mutational analysis of selected genes
(Galuppini et al., 2019).
The limitations of the efficacy of immune checkpoint blockade
therapies highlight the need for improving predictive strategies and
finding novel synergistic therapeutic targets to increase the response
rate and/or the number of patients that can be treated.
5 | COMBINED THERAPIES TO IMPROVE
IMMUNE CHECKPOINT BLOCKADE
EFFICACY
A great effort has been done recently to explore the possible advan-
tages of combining the blockade of multiple inhibitory signals at the
same time, targeting NK cells together with T cells, neutralizing inhibi-
tory molecules present at the tumour site or increasing tumour immu-
nogenicity through radiotherapy (RT).
5.1 | Immune checkpoint inhibitor (ICI) and tumour
immunosuppressive micro-environment
A major role in the failure of immune checkpoint therapies is played
by the TME. For instance, hypoxia is responsible for the generation of
adenosine, which decreases proliferation and effector function of
cytotoxic lymphocytes (Cekic, Day, Sag, & Linden, 2014). Adenosine is
generated by the sequential degradation of ATP to AMP, and AMP
dephosphorylation, by CD39 and CD73, respectively. A combination
of anti-CD73 and anti-PD-1 treatments has been tested in patients
with advanced solid tumours and anti-tumour activity has been pre-
liminary reported (Siu et al., 2018), and several other molecules that
target the adenosine releasing pathway are currently in clinical devel-
opment (Perrot et al., 2019). Another enzyme present in the TME is
the indoleamine 2,3-dioxygenase (IDO), which catalyses tryptophan
degradation leading to deprivation of this amino acid and kynurenine
production. Both these events contribute to tumour tolerance acting
on the differentiation of regulatory T cells (Tregs) and directly
suppressing Tand NK cell function and proliferation (Della Chiesa
et al., 2006; Munn & Mellor, 2007). Indeed, it was shown that IDO
mediates resistance to anti-CTLA4 and PD-1 therapies (Holmgaard,
Zamarin, Munn, Wolchok, & Allison, 2013), but to date, no significant
benefit has been revealed by combined IDO and PD-1/PD-L1 axis
inhibition in melanoma (Long et al., 2019). Another component of the
TME that contributes to the evasion of immune surveillance and to
the failure of immune checkpoint blockade is TGFβ (Mariathasan
et al., 2018). TGFβ excludes immune cells from the tumour bed
(Tauriello et al., 2018) and inhibits bothT cells and NK cell cytotoxicity
(Castriconi et al., 2013; Gao et al., 2017; Viel et al., 2016). A first-in-
class bifunctional checkpoint inhibitor (the fusion protein M7824)
comprising the extracellular domain of human TGFβRII (TGFβ Trap)
linked to the C-terminus of human anti-PD-L1 heavy chain (αPD-L1)
F IGURE 2 Different approaches to enhance immune response. Despite the development of new therapeutic approaches targeting the
inhibitory checkpoints, the percentage of patients responding to anti-PD-1 immunotherapy remained low. Different strategies can be adopted to
improve both the immune response prediction and efficacy. A more in-depth analysis of tumour mutational burden (TMB) and a better
characterization of PD-L1 expression at tumour site will allow a more accurate diagnosis. In addition, improvement of immune checkpoint
blockade response can be obtained combining different therapeutic approaches
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has been developed and has proved to be efficient in promoting T-cell
and NK cell activation in mouse tumour models (Knudson
et al., 2018). These findings prove that simultaneous targeting of
TGFβ and PD-L1/PD-1 immunosuppressive pathways may represent
a promising tool to promote anti-tumour responses (Figure 2).
5.2 | Combination of ICI targeting different
pathways
Another strategy to improve the efficacy of checkpoint blockade is to
target multiple checkpoints at the same time. Indeed, several studies
demonstrated that the combined blockade of multiple inhibitory
checkpoints resulted to be more effective in controlling tumour
growth compared with blockade of a single receptor (Nirschl &
Drake, 2013). These data confirmed the hypothesis that combined
immune checkpoint blockade could be an innovative and potential
treatment strategy to be applied to a wide variety of cancers
(Figure 2). In addition, this notion revealed that inhibitory checkpoints
might synergize to down-modulate the overall antit-umour immune
response. Among the inhibitory receptors expressed by NK cells, a
promising target for combined therapy is NKG2A, which has the
advantage of being expressed also by activated T cells (Bertone
et al., 1999; Mingari, Ponte, et al., 1998) and whose ligand (HLA-E) is
frequently overexpressed in tumours. NKG2A blockade with the
mAbs monalizumab in combination with the blockade of the PD-1/
PD-L1 axis was proved to enhance both T-cell and NK cell responses
(Andre et al., 2018). Moreover, blocking NKG2A increased NK cell
antibody-dependent cell-mediated cytotoxicity, thus enhancing the
efficacy of cetuximab (an anti-estimated GFR [anti-EGFR] antibody)
treatment in patients with squamous cell carcinoma of the head
and neck SCCHN (Andre et al., 2018). These findings suggest that
targeting NKG2A may represent a complementary tool to unleash NK
cell response by combining checkpoint inhibitors with monoclonal
antibodies targeting tumour antigens. In addition, combined immuno-
therapies targeting PD-1 and other inhibitory checkpoints are under
investigation. Thus, IMP321, a clinical-grade sLAG-3 protein, is cur-
rently used in combination with anti-PD-1 therapy in phase II clinical
trials. Moreover, the efficacy of an anti-LAG3 monoclonal antibodies
(relatlimab) is currently being investigated in several types of cancer
(NCT02061761; NCT02658981). As mentioned before, TIM3 and
PD-1 are often found to be co-expressed on NK cells from cancer
patients. Thus, anti-TIM3-blocking monoclonal antibodies have been
used in combination with anti-PD-1 in phase I clinical trials to block
tumour growth and restore the anti-tumour immune response
(Chiossone & Vivier, 2017). Moreover, the inhibitory receptor T-cell
immunoglobulin and ITIM domain has been shown to act in synergy
with both PD-1 and TIM3 (Kurtulus et al., 2015). Indeed, combined
blockade of TIGIT and TIM3 or PD-1 resulted in tumour regression
and increased anti-tumour immunity. In this context, anti-PD-1 ther-
apy combined with a fully human anti-TIGIT monoclonal antibody
(MTIG7192A, RG6058) is tested in a phase I clinical trial towards dif-
ferent solid tumours.
Moreover, due to the potent inhibitory effect exerted by KIRs on
NK cell function, a human monoclonal antibodies blocking KIR2DL1,
KIR2DL2 and KIR2DL3 on NK cells, namely, lirilumab, was developed.
In clinical trials for acute myeloid leukaemia (AML), myeloma or solid
tumours, lirilumab showed, however, limited anti-tumour efficacy
(Carlsten et al., 2016) (Vey et al., 2018). By contrast, IPH4102, a first-
in-class monoclonal antibodies targeting KIR3DL2 is showing encour-
aging clinical activity in patients with cutaneous T-cell lymphoma
(Bagot et al., 2019). In addition, several approaches have been devel-
oped to block the HLA-G/ILT signalling pathway, which take into
account also the different mechanism regulating HLA-G surface
expression. These approaches include HLA-G antagonists, blocking
antibodies against HLA-G or its receptors, siRNA, inhibition of its
intercellular transfer and HLA-G as target for drug delivery
(Li et al., 2017; Lin & Yan, 2019; Zhang et al., 2014). Therefore, KIRs
and HLA-G may also represent promising targets for combined
therapy.
5.3 | ICI and radiotherapy
Radiotherapy (RT) is an essential treatment for cancer patients
(Ngwa et al., 2018). It has been widely demonstrated that RT is
able to modulate the anti-tumour response acting, through differ-
ent mechanisms, on the TME. Indeed, it reduces the overall tumour
burden increasing systemic responses to immunotherapy, and in
addition, preclinical models showed several immune-stimulatory
effects of ionizing radiations. These include activation of pro-death
signalling in tumour cells and release of damage-associated molecu-
lar patterns and ‘eat me’ signals. Of note, RT can also serve as an
in situ vaccine, promoting the release of tumour-associated anti-
gens (TAAs) and enhancing the number of APC cells in both the
tumour micro-environment and lymph nodes with
consequent enhanced dendritic cell activation, T-cell priming and
recruitment of CD8+ T lymphocytes (Hwang, Pike, Royce, Mahal, &
Loeffler, 2018). In addition, RT can modulate the innate immune
response, increasing NK cell-mediated cytotoxicity through the up-
regulation of NK cell-activating receptor, NKG2D and NKp30,
expression (Kim et al., 2006) (Matta et al., 2013). Moreover, it has
been demonstrated that the interaction of RT with patient immune
system is essential to promote the abscopal effect (AbE), which
represents a promising tool to use abscopal effect for the treat-
ment of not only localized tumours but also metastases (Ngwa
et al., 2018). AbE was first observed in 1953 and it describes the
systemic anti-tumour reactions upon RT treatment that can lead to
regression of lesions in metastases outside the radiation field
(Mole, 1953). However, on the other side, RT may also impair the
anti-tumour immune responses increasing the influx of MDSC and
Tregs and promoting the release of inflammatory cytokines, which
can also induce PD-L1 expression (Gandhi et al., 2015) (Deng
et al., 2014). Thus, considering the important achievements
obtained with ICI in targeting the immune response and, at the
same time, the fact that not all patients benefit of ICI or RT
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treatment alone, increase interest raised for the integration of
immune checkpoint blockade with RT for the treatment of patients
with numerically and spatially restricted areas of metastasis
(Pitroda, Chmura, & Weichselbaum, 2019). More importantly, com-
bination of RT and ICI represents a great opportunity to boost
AbE rates. Indeed, preclinical studies demonstrated that regression
of non-irradiated lesions can only be observed in immunocompe-
tent mice, indicating that despite the increase of tumour immuno-
genicity, RT alone is not sufficient to induce AbE (Demaria
et al., 2004). Several reports indicated that AbE is mainly observed
in highly immunogenic tumours, such as malignant melanoma, renal
cell carcinoma, hepatocellular carcinoma and NSCLC. Importantly,
several immunotherapeutic agents, targeting different mechanisms
of immune-mediated responses, are able to boost AbE (Ngwa
et al., 2018). In particular, preclinical studies indicate that PD-1/
PD-L1 blockade is optimal in combination with RT. Indeed, an
enhancement of anti-tumour effects and significant reduction of
secondary non-irradiated tumours was observed in mice model,
bearing solid or haematological tumours, treated with in-field RT in
combination with PD-1 or PD-L1 blockers (Gong, Le, Massarelli,
Hendifar, & Tuli, 2018). Clinical studies confirmed that combination
of anti-PD-1 or anti-PD-L1 immunotherapies with RT was associ-
ated with clinical significant and durable tumour responses in dif-
ferent cancer patients (Haymaker et al., 2017) (Yuan et al., 2017)
(Takamori et al., 2018) (Xie, Gu, Zhang, Chen, & Wu, 2017).
However, some limitations have also emerged from experimental
and clinical data (Ngwa et al., 2018). Despite the boost of the immune
response, the presence of immune suppressive environment
(i.e. MDSC and Treg cells and/or immunosuppressive cytokines) or
tolerance at the tumour sites can repress AbE. Immune-related
adverse events can be also due to the overlapping toxicities derived
from RT and ICI combination (Vanneman & Dranoff, 2012). More
importantly, despite the numerous preclinical and clinical studies, the
mechanisms underlying AbE have not yet been identified. Therefore,
it is essential to develop new strategies to overcome these limitations
and improve our understanding of the biological pathway regulating
AbE. In this context, numerous preclinical studies have explored a
range of radiation regimens combined with immune checkpoint block-
ade to optimize synergy with immunotherapy (Patel & Minn, 2018)
(Figure 2). However, since the radiation dose, fractionation, timing
and target organs are still not well defined, additional clinical studies
are needed to fully realize the potential of integrated radio-immuno-
therapies. Under investigation studies, aimed to minimize the effect of
immunosuppression, use different approaches to improveT-cell stimu-
lation primed by RT and/or immunotherapy. Moreover, considering
that AbE is more often associated to highly immunogenic tumours, it
is essential to develop new strategies to increase immunogenicity. In
this context, preclinical models demonstrated that RT, ICI and antican-
cer vaccine combination could increase abscopal effect response rates
(Zheng et al., 2016). Overall, despite the multiple challenges in over-
coming cancer immunosuppression, there is an increasing interest in
developing new strategies to boost AbE in order to improve patient
outcomes.
6 | CHIMERIC ANTIGEN RECEPTOR-
ENGINEERED NK CELLS
In the field of tumour immunotherapy, a complementary approach
to unleash cytotoxic lymphocytes through ICI is represented by the
development of chimeric antigen receptor (CAR)-cells. This approach
is based on engineering cells with synthetic receptors in order to
combine their high anti-tumour activity with the capability of
tumour antigen recognition of antibodies. This promising technique
was first used to engineer T cells generating CAR-T cells (Singh &
McGuirk, 2020). The expression of synthetic receptors instead of
the physiological TCR allows CAR-T cells to recognize any cell sur-
face molecule independently of MHC presentation, thus broadening
the array of antigens recognized by T cells. Several approaches to
generate CAR-T cells have been developed in order to maximize
their activity, persistence and expansion (Depil, Duchateau, Grupp,
Mufti, & Poirot, 2020). Since their development, adoptive cell trans-
fer of chimeric antigen receptor T cells revealed successful in the
treatment of high-risk B-cell lymphoma and lymphoblastic leukaemia
(Neelapu et al., 2017) (Park et al., 2018). Despite the important suc-
cess in the treatment of haematological malignancies, similar results
have not been obtained so far in solid tumours. However, in this
context, it is worth to mention the recent development of a CAR-T
cells against the HLA-G molecule in order to elicit immune response
against HLA-G+ solid tumours (presentation at the ESMO Immuno-
Oncology Congress 2019, Geneva, Switzerland Volume 30, Supple-
ment 11, Loustau, M. Annals of Oncology, Volume 30, xi12). Never-
theless, some obstacles limit chimeric antigen receptor T clinical
application, such as: high cost, need of personalized production that
requires a substantial delay between patient enrolment
and treatment, cytokine release syndrome and neurotoxicity
(Sivori et al., 2019). On the contrary, NK cells engineering could
represent an appealing solution. Indeed, chimeric antigen receptor
NK cells do not require HLA matching and can be administered in
allogenic settings without causing graft versus host disease (GvDH)
providing a cost-effective ‘off-the-shelf’ product (Burger
et al., 2019) (Zhang, Hu, & Shi, 2020). In addition, due to the
expression of activating receptors, such as NCR, NKG2D, DNAM-1
and CD16, NK cells are able to induce cytotoxicity in both CAR-
dependent and -independent manners reducing the eventuality of
loss of CAR-targeting antigen-related relapses and increasing their
killing activity (Hu, Tian, & Zhang, 2018). Different sources for the
isolation and generation of genetically engineered NK cells exist,
including peripheral blood and umbilical cord blood (UCB) NK cells,
various human NK cell lines (NK92, YT, KHYG, etc.) and induced
pluripotent stem cell (iPSC)-derived NK cells. Several clinical trials
are evaluating the efficiency of chimeric antigen receptor NK92
cells in haematological malignancies and multiple myeloma as well
as in glioblastoma (Chu et al., 2014) (Han et al., 2015) (Zhang
et al., 2020). However, irradiated NK92 cannot expand in vivo after
infusion, and lacking the expression of CD16 and NKp44, the
ADCC and the natural cytotoxicity, proper of activated primary NK
cells, are compromised, making the NK92 cell line not the most
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reliable source for NK cell engineering (Sivori, Meazza, et al., 2019).
For this reason, UCB-, PB- and iPSC-derived NK cells have also
been used as possible source for the development of CAR-NK cells.
Several attempts have been made to identify the best protocol for
PB-NK expansion, and an innovative strategy, which does not
require a feeder layer, has been developed and successfully tested
for CAR-CD19 NK cells (Quintarelli et al., 2020). CAR-NK cells
derived from iPSC also demonstrated potent ability to kill, both
in vitro and in vivo, mesothelin-expressing tumours
(Li, Hermanson, Moriarity, & Kaufman, 2018). iPSC-NK cells repre-
sent an innovative and particularly promising tool because they effi-
ciently kill both haematological malignancies and solid tumours, and
most importantly, they are reproducible and can be easily geneti-
cally modified and expanded on the clinical scale (Zhang
et al., 2020).
However, low in vivo persistence, immunosuppression exerted
by TME and difficulty to infiltrate into solid tumours represent
other challenges for CAR-NK clinical applications (Zhang
et al., 2020). Thus, CAR constructs have been optimized according
to NK cell features. NKG2D-expressing CAR-NK cells gave encour-
aging results in a mouse model of osteosarcoma, as they could rec-
ognize different tumour cells as well as immunosuppressive cells
(MDSC and Tregs) present in the TME (Parihar et al., 2019). More-
over, a chimeric PD-1–NKG2D construct was also used to increase
NK92 killing against various tumour cells (Guo et al., 2019). CAR-
NK cells can also be engineered with IL-15 and/or chemokine
receptors in order to increase specificity, efficacy and safety
properties.
Even though there are still relevant challenges that impair a wide-
spread use of CAR-NK cell-based therapies including improvement of
ex vivo expansion, CAR construct optimization and development of
new strategies to dampen the TME immunosuppression, NK cell ther-
apy represent a promising and powerful tool for a more affordable
‘off-the-shelf’ cancer immunotherapy.
7 | CONCLUDING REMARKS
Recent years have witnessed an extraordinary progress in cancer ther-
apy. The major advances are related to the use of checkpoint inhibi-
tors, which dramatically changed the clinical outcome of cancer
patients. Notably, the most efficient responses have been obtained in
highly aggressive, metastatic tumours, primarily melanoma and
NSCLC. These results have been explained with the high rate of
genetic mutations of these tumours. Indeed, a direct correlation has
been established between responses to checkpoint inhibitory treat-
ment and mutation rates of different tumour types. A likely explana-
tion is that genetic mutations, upon altering proteins, generate new
tumour antigens recognized by T cells in an HLA-restricted fashion.
However, HLA-I partial or total losses are a major mechanism of
tumour escape and selection of tumour cells clones that became
‘invisible’ to T lymphocytes. In this respect, NK cells, different from T
cells, efficiently kill HLA-I-deficient tumour cells, representing useful
effectors to attack these tumours. In this context, harnessing NK cell
function should represent a major focus of present and future immu-
notherapy. Indeed, the function of inhibitory checkpoints expressed
by NK cells, their biology and role in tumour immunotherapy, particu-
larly in combination therapies, should be further investigated. Other
strategies should also be examined in depth. A more promising
approach is represented by NK cells that have been genetically modi-
fied to express CAR directed to tumour surface antigens. Different
from chimeric antigen receptor T cells that must be used in an autolo-
gous setting (allogenic T cells would cause a severe GVHD), allogenic
NK cells do not cause GVHD. Thus, donor-derived CAR-NK cells may
be safely used for cancer treatment. This current technology allows
obtaining large number of CAR-NK cells in vitro with a 4-log expan-
sion, while their survival and expansion in vivo may be overcome by
the additional transfection with IL-15-inducing gene. Notably, CAR-
NK cells may represent optimal ‘off-the-shelf’ donor-derived products,
since they can be prepared in large scale, with markedly reduced
costs. In addition, they are immediately available to cancer patients in
need of treatment and may be administered according to well-defined
protocols, as to the timing and the number of cell infused. The possi-
ble benefit of CAR-NK approach in combination with checkpoint
inhibitors should also be examined.
In conclusion, both major discoveries in the past three decades
and the continuous technological advances have provided a large
armamentarium that allowed and will allow improving treatment of
high-risk leukaemia and solid tumours. In this context, NK-based ther-
apies may play a fundamental role.
7.1 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in https://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY (Armstrong et al., 2020) and are permanently archived in
the Concise Guide to PHARMACOLOGY 2019/2020 (Alexander
et al., 2019).
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